T. E. Witzig, C. A. White, G. A. Wiseman, L. I. Gordon, C. Emmanouilides et al., Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 + B-cell non-Hodgkin's lymphoma, J Clin Oncol, vol.17, pp.3793-3803, 1999.

I. Navarro-teulon, C. Lozza, A. Pèlegrin, E. Vivès, and J. Pouget, General overview of radioimmunotherapy of solid tumors, Immunotherapy, vol.5, pp.467-487, 2013.

M. Altai, R. Membreno, B. Cook, V. Tolmachev, and B. M. Zeglis, Pretargeted imaging and therapy, J Nucl Med, vol.58, pp.1553-1559, 2017.

D. J. Hnatowich, F. Virzi, and M. Rusckowski, Investigations of avidin and biotin for imaging applications, J Nucl Med, vol.28, pp.1294-1302, 1987.

D. A. Goodwin, C. F. Meares, M. J. Mccall, M. Mctigue, and W. Chaovapong, Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens, J Nucl Med, vol.29, pp.226-234, 1988.

P. Magnani, F. Fazio, C. Grana, C. Songini, L. Frigerio et al., Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy, Br J Cancer, vol.82, pp.616-620, 2000.

F. Kraeber-bodéré, J. Barbet, and J. Chatal, Radioimmunotherapy: from current clinical success to future industrial breakthrough?, J Nucl Med, vol.57, pp.329-331, 2016.

J. Summerton, D. Stein, S. B. Huang, P. Matthews, D. Weller et al., Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems, Antisense Nucleic Acid Drug Dev, vol.7, pp.63-70, 1997.

G. Liu, S. Dou, Y. Liu, Y. Wang, M. Rusckowski et al., 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy, Bioconjug Chem, vol.22, pp.2539-2545, 2011.

G. Mardirossian, K. Lei, M. Rusckowski, F. Chang, T. Qu et al., In vivo hybridization of technetium-99m-labeled peptide nucleic acid (PNA), J Nucl Med, vol.38, pp.907-913, 1997.

M. L. Blackman, M. Royzen, and J. M. Fox, Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels?Alder reactivity, J Am Chem Soc, vol.130, pp.13518-13519, 2008.

R. Rossin, S. M. Van-den-bosch, W. Ten-hoeve, M. Carvelli, R. M. Versteegen et al., Highly reactive trans cyclooctene tags with improved stability for DielsAlder chemistry in living systems, Bioconjug Chem, vol.24, pp.1210-1217, 2013.

A. Darko, S. Wallace, O. Dmitrenko, M. M. Machovina, R. A. Mehl et al., Conformationally strained trans-cyclooctene with improved stability and excellent reactivity in tetrazine ligation, Chem Sci, vol.5, pp.3770-3776, 2014.

R. Rossin, P. R. Verkerk, S. M. Van-den-bosch, R. C. Vulders, I. Verel et al., In vivo chemistry for pretargeted tumor imaging in live mice, Angew Chem Int Ed Engl, vol.49, pp.3375-3378, 2010.

R. Rossin, S. Van-duijnhoven, T. Läppchen, S. M. Van-den-bosch, and M. S. Robillard, Trans-cyclooctene tag with improved properties for tumor pretargeting with the Diels-Alder reaction, Mol Pharm, vol.11, pp.3090-3096, 2014.

J. L. Houghton, B. M. Zeglis, D. Abdel-atti, R. Sawada, W. W. Scholz et al., Pretargeted immuno-PET of pancreatic cancer: overcoming circulating antigen and internalized antibody to reduce radiation doses, J Nucl Med, vol.57, pp.453-459, 2016.

J. L. Houghton, R. Membreno, D. Abdel-atti, K. M. Cunanan, S. Carlin et al., Establishment of the in vivo efficacy of pretargeted radioimmunotherapy utilizing inverse electron demand Diels-Alder click chemistry, Mol Cancer Ther, vol.16, pp.124-133, 2017.

R. Membreno, B. E. Cook, K. Fung, J. S. Lewis, and B. M. Zeglis, Click-mediated pretargeted radioimmunotherapy of colorectal carcinoma, Mol Pharm, vol.15, pp.1729-1734, 2018.

F. Coccolini, F. Gheza, M. Lotti, S. Virzì, D. Iusco et al., Peritoneal carcinomatosis. World J Gastroenterol, vol.19, pp.6979-6994, 2013.

E. J. Kuipers, W. M. Grady, D. Lieberman, T. Seufferlein, J. J. Sung et al., Colorectal cancer. Nat Rev Dis Primers, vol.1, p.15065, 2015.

D. Massalou, E. Benizri, A. Chevallier, V. Duranton-tanneur, F. Pedeutour et al., Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes, Am J Surg, vol.213, pp.377-387, 2017.

M. Hornung, J. M. Werner, and H. J. Schlitt, Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer, Expert Rev Anticancer Ther, vol.17, pp.841-850, 2017.

K. Murono, K. Kawai, K. Hata, S. Emoto, M. Kaneko et al., Regimens of intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer, Anticancer Res, vol.38, pp.15-22, 2018.

P. H. Sugarbaker, Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis, Semin Surg Oncol, vol.14, pp.254-261, 1998.

V. J. Verwaal, S. Bruin, H. Boot, G. Van-slooten, and H. Van-tinteren, 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer, Ann Surg Oncol, vol.15, pp.2426-2432, 2008.

H. J. Braam, T. R. Van-oudheusden, I. H. De-hingh, S. W. Nienhuijs, D. Boerma et al., Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer: Recurrence Following HIPEC, J Surg Oncol, vol.109, pp.841-847, 2014.

M. Ychou, D. Azria, C. Menkarios, P. Faurous, F. Quenet et al., Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer, Clin Cancer Res, vol.14, pp.3487-3493, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00292535

H. Hanaoka, M. Kuroki, A. Yamaguchi, A. Achmad, Y. Iida et al., Fractionated radioimmunotherapy with 90Y-labeled fully human anti-CEA antibody, Cancer Biother Radiopharm, vol.29, pp.70-76, 2014.

F. Aarts, T. Hendriks, O. C. Boerman, M. J. Koppe, W. Oyen et al., A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats, Ann Surg Oncol, vol.14, pp.3274-3282, 2007.

G. M. De-jong, R. P. Bleichrodt, A. Eek, W. Oyen, O. C. Boerman et al., Experimental study of radioimmunotherapy versus chemotherapy for colorectal cancer, Br J Surg, vol.98, pp.436-441, 2011.

V. Boudousq, S. Ricaud, V. Garambois, C. Bascoul-mollevi, S. Boutaleb et al., Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies, J Nucl Med, vol.51, pp.1748-1755, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00531603

E. Deshayes, R. Ladjohounlou, L. Fur, P. Pichard, A. Lozza et al., Radiolabeled antibodies against müllerian-inhibiting substance receptor, type II: new tools for a theranostic approach in ovarian cancer, J Nucl Med, vol.59, pp.1234-1242, 2018.

V. Boudousq, L. Bobyk, M. Busson, V. Garambois, M. Jarlier et al., Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb, Plos One, vol.8, p.69613, 2013.

B. D. Nicholson, B. Shinkins, I. Pathiraja, N. W. Roberts, T. J. James et al., Blood CEA levels for detecting recurrent colorectal cancer, Cochrane Database Syst Rev, vol.12, p.11134, 2015.

P. H. Cashin, W. Graf, P. Nygren, and H. Mahteme, Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an observational cohort study, Ann Surg, vol.256, pp.1078-1083, 2012.

L. Santoro, S. Boutaleb, V. Garambois, C. Bascoul-mollevi, V. Boudousq et al., Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis, J Nucl Med, vol.50, pp.2033-2041, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00442929

A. Rondon, N. Ty, J. Bequignat, M. Quintana, A. Briat et al., Antibody PEGylation in bioorthogonal pretargeting with trans-cyclooctene/tetrazine cycloaddition: in vitro and in vivo evaluation in colorectal cancer models, Sci Rep, vol.7, p.14918, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01646770

W. E. Bolch, K. F. Eckerman, G. Sgouros, and S. R. Thomas, MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature, J Nucl Med, vol.50, pp.477-484, 2009.

S. Jan, G. Santin, D. Strul, S. Staelens, K. Assié et al., GATE: a simulation toolkit for PET and SPECT, Phys Med Biol, vol.49, pp.4543-4561, 2004.
URL : https://hal.archives-ouvertes.fr/in2p3-00021834

S. Jan, D. Benoit, E. Becheva, T. Carlier, F. Cassol et al., GATE V6: a major enhancement of the GATE simulation platform enabling modelling of CT and radiotherapy, Phys Med Biol, vol.56, pp.881-901, 2011.
URL : https://hal.archives-ouvertes.fr/in2p3-00559709

D. Sarrut, M. Bardiès, N. Boussion, N. Freud, J. M. Létang et al., A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications, Med Phys, vol.41, p.64301, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01015819

A. Maisonial-besset, T. Witkowski, I. Navarro-teulon, O. Berthier-vergnes, G. Fois et al., Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer, Oncotarget, vol.8, pp.22034-22047, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01611133

Y. L. Klaver, T. Hendriks, R. M. Lomme, H. J. Rutten, R. P. Bleichrodt et al., Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for peritoneal carcinomatosis in an experimental model, Br J Surg, vol.97, pp.1874-1880, 2010.

N. J. Harlaar, M. Koller, S. J. De-jongh, B. L. Van-leeuwen, P. H. Hemmer et al., Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study, Lancet Gastroenterol Hepatol, vol.1, pp.283-290, 2016.

E. Stéen, P. E. Edem, K. Nørregaard, J. T. Jørgensen, V. Shalqunov et al., Pretargeting in nuclear imaging and radionuclide therapy: improving efficacy of theranostics and nanomedicines, Biomaterials, vol.179, pp.209-245, 2018.

P. B. Lawrence and J. L. Price, How PEGylation influences protein conformational stability, Curr Opin Chem Biol, vol.34, pp.88-94, 2016.

X. Zhang, H. Wang, Z. Ma, and B. Wu, Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns, Expert Opin Drug Metab Toxicol, vol.10, pp.1691-1702, 2014.

T. Läppchen, R. Rossin, T. R. Van-mourik, G. Gruntz, F. Hoeben et al., DOTA-tetrazine probes with modified linkers for tumor pretargeting, Nucl Med Biol, vol.55, pp.19-26, 2017.

S. Mayer and K. Lang, Tetrazines in inverse-electron-demand Diels-Alder cycloadditions and their use in biology, Synthesis, vol.49, pp.830-848, 2016.

R. Rossin, T. Läppchen, S. M. Van-den-bosch, R. Laforest, and M. S. Robillard, Diels-Alder reaction for tumor pretargeting: in vivo chemistry can boost tumor radiation dose compared with directly labeled antibody, J Nucl Med, vol.54, pp.1989-1995, 2013.